Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?

• Sponsor: Huazhong University of Science and Technology (Other)
• Overall Status: Completed
• CT.gov ID: NCT00733200
• Collaborator: Ministry of Health, China (Other), Hepatic Surgery Clinical Research Centre of Hubei, China (Other)
• Arm: 1

Study Details

Study Description

Brief Summary

The investigators conducted a prospective study to determine the safety and efficacy of minor and major hepatectomy selected by predetermined criteria in 138 patients with hilar cholangiocarcinoma. In selected patients, minor liver resection was a good treatment.

Condition or Disease	Intervention/Treatment	Phase
Cholangiocarcinoma; Surgical Treatment; Hepatectomy	Procedure: Minor or Major Liver Resection	N/A

Detailed Description

Objective: To determine the safety and efficacy of minor and major hepatectomy selected by predetermined criteria in patients with hilar cholangiocarcinoma (HC).

Summary Background Data: For HC treated with hepatectomy, the extent of liver resection remains controversial despite extensive studies.

Methods: From January 2000 to December 2007, we prospectively studied patients who received surgical treatment for HC. Of the 187 patients who were surgically treated, 138 (73.8%) underwent resection with a curative intent. Minor hepatectomy was carried out in 93 patients who had Bismuth-Corlette types I, II and III HC without hepatic artery/portal vein invasion; and major hepatectomy in 45 patients who had type III HC with hepatic artery/portal vein invasion, or type IV HC.

Study Design

• Study Type: Interventional
• Official Title: Surgical Treatment of Hilar Cholangiocarcinoma: Minor or Major Liver Resection?

Arms and Interventions

Arm	Intervention/Treatment
No Intervention: Control group	Procedure: Minor or Major Liver Resection

Outcome Measures

Primary Outcome Measures

1. On multivariate analysis, prognostic factors significantly impacted on long-term survival were UICC tumor stage and histopathologic grade. []

Eligibility Criteria

Criteria

• Ages Eligible for Study: 26 Years to 72 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Criteria for resectability were absence of peritoneal or liver metastases, tumor extension to beyond secondary biliary branches bilaterally, tumor extension to secondary portal venous branches bilaterally

Exclusion Criteria:

• not in accordance with the above criteria

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

• Huazhong University of Science and Technology
• Ministry of Health, China
• Hepatic Surgery Clinical Research Centre of Hubei, China

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• ClinicalTrials.gov Identifier: NCT00733200
• Other Study ID Numbers: chenxp002
• First Posted: Aug 12, 2008
• Last Update Posted: Dec 11, 2009
• Last Verified: Aug 1, 2008

• Keywords provided by , ,: Minor Liver Resection; Major Liver Resection; Hilar
• Additional relevant MeSH terms: Cholangiocarcinoma; Klatskin Tumor

Study Results

No Results Posted as of Dec 11, 2009